Cytokinetics Presents Additional 48-Week Data From FOREST-HCM, the Open Label Extension ...

SOUTH SAN FRANCISCO, Calif., April 05, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced additional 48-week data from FOREST-HCM (Follow-up, Open-Label, Research Evaluation of Sustained Treatment with Aficamten

Related Keywords

China ,United States ,Fadyi Malik ,Diane Weiser ,Clinical Trials Program For Aficamten ,American College Of Cardiology ,Youtube ,Corporate Affairs ,Exchange Commission ,Research Development ,Linkedin ,Facebook ,Us Food Drug Administration ,Research Evaluation Of Sustained Treatment ,National Medical Products Administration ,Symphony Health ,Cytokinetics Incorporated Nasdaq ,Journal Of The American College Cardiology ,Research Evaluation ,Sustained Treatment ,Annual American College ,Scientific Session ,Cytokinetic Executive Vice President ,Broad Phase ,Trials Program ,Quantitative Understanding ,Obstruction Impact ,Exercise Capacity ,Assessment Comparing Aficamten ,Cardiac Endpoints In Adults ,Breakthrough Therapy Designation ,Drug Administration ,Private Securities Litigation Reform Act ,Safe Harbor ,Vice President ,Heart Failure ,Claims Data Dof ,Clinically Diagnosed Hypertrophic Cardiomyopathy ,American College ,American Heart Association Task Force ,Region ,